Cytori Partner Kerastem Completes Enrollment of US Phase II Trial for Early Stage Hair Loss
September 26 2016 - 7:00AM
Business Wire
Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced today that its
licensee Kerastem Technologies, LLC, has completed enrollment
of STYLE, a US phase II clinical trial investigating early stage
female and male pattern hair loss.
“Cytori Cell Therapy is a broadly applicable cell therapeutic
platform used now in multiple mid and late stage clinical trials in
the US, Japan and Europe. Our partner Kerastem is focused on
developing Cytori technology for men and women with alopecia,” said
Dr. Marc H. Hedrick, President & CEO of Cytori. “Early proof of
concept clinical data has shown promise and Kerastem expects a read
out from the trial in approximately one year. This therapy if
approved could create a significant value for our
stockholders.”
STYLE is a phase II randomized, blinded, and controlled
investigation of Kerastem therapy in early stage female and male
pattern baldness. A total of four clinical trial sites treated a
target enrollment of 70 patients in the United States. The primary
endpoint of STYLE is safety and tolerability at six months and
subjects will be followed for 12 months. Subjects participating in
STYLE received one of four treatment arms, including fat plus
ADRCs.
Outside of the United States, Kerastem is actively involved in
market development, with Kerastem therapy currently being offered
at a number of clinics in Europe & Japan.
To learn more about Kerastem or the STYLE Clinical Trial, please
visit www.kerastem.com or
https://clinicaltrials.gov/ct2/show/NCT02503852?term=Kerastem&rank=1
About Cytori
Cytori Therapeutics is a late stage cell therapy company
developing autologous cell therapies from adipose tissue to treat a
variety of medical conditions. Data from preclinical studies and
clinical trials suggest that Cytori Cell Therapy™ acts principally
by improving blood flow, modulating the immune system, and
facilitating wound repair. As a result, Cytori Cell Therapy™ may
provide benefits across multiple disease states and can be made
available to the physician and patient at the point-of-care through
Cytori’s proprietary technologies and products. For more
information visit www.cytori.com.
About Kerastem
Kerastem Technologies, LLC is a private company owned by Bimini
Technologies, and holds global rights to commercialize Cytori Cell
Therapy for alopecia and hair related indications. The Bimini
portfolio of products also includes Puregraft, the world’s leading
fat grafting solution.
Cautionary Statement Regarding Forward-Looking
Statements
This press release includes forward-looking statements regarding
events, trends and business prospects, which may affect our future
operating results and financial position. Such statements,
including, without limitation, statements regarding STYLE clinical
data and potential benefits to Cytori and its stockholders if
Cytori Cell Thearapy is approved for alopecia, are all subject to
risks and uncertainties that could cause our actual results and
financial position to differ materially. Some of these risks and
uncertainties include, but are not limited to, inherent risk and
uncertainty in the protection intellectual property rights,
regulatory uncertainties, risks in the conduct of clinical trials
(including clinical trial conducted by third parties), risks in the
collection and results of clinical data, final clinical outcomes,
dependence on third party performance, performance (including
performance under and compliance with the terms of our contracts
with such third parties) and acceptance of our products in the
marketplace, as well as other risks and uncertainties described
under the heading "Risk Factors" in Cytori's Securities and
Exchange Commission Filings on Form 10-K and Form 10-Q. We assume
no responsibility to update or revise any forward-looking
statements to reflect events, trends or circumstances after the
date they are made.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160926005440/en/
Cytori Therapeutics, Inc.Tiago Girao, +1
858-458-0900ir@cytori.com
Cytori Therapeutics (NASDAQ:CYTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cytori Therapeutics (NASDAQ:CYTX)
Historical Stock Chart
From Sep 2023 to Sep 2024